

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Keohane C, Radia DH, Harrison CN. *Biologics: Targets and Therapy*. 2013;7:189–198.

On page 193 note that the paragraph beginning “Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts ($<50 \times 10^9/L$),” should have been “Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts ($<50 \times 10^9/L$).”

On page 193 in the same paragraph note that “Post-Essential Thrombocythemia Myelofibrosis: PERSIST)” should have been “Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1).”

Biologics: Targets & Therapy

Publish your work in this journal

Biologics: Targets & Therapy is an international, peer-reviewed journal focusing on the patho-physiological rationale for and clinical application of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified. This journal is indexed on PubMed Central, CAS, EMBase, Scopus

Submit your manuscript here: <http://www.dovepress.com/biologics-targets--therapy-journal>

and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.